Docket #: S21-012
System biological analysis of vaccination for mechanisms of adjuvanticity and antibody durability in humans
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health. Rapid development of vaccines is critical for the prevention and control of such pandemics. As part of this goal, adjuvants are key components of vaccines that can potentially increase the strength, durability, and breadth of the immune response. Unfortunately, the mechanisms that determine how adjuvants work are, in many cases, poorly understood. This new method allows for the determination of vaccine and adjuvant efficacy in provoking strong and durable immune responses based on gene expression changes in as little as one day post-injection, providing a substantial benefit in shortening the time required to evaluate vaccine and adjuvant effectiveness.
This technology is part of a portfolio of innovations aimed at fighting the COVID-19 pandemic.
Stage of Research
Applications
- Rapid vaccine/adjuvant development
- Rapid vaccine/adjuvant testing, benchmarking, and evaluation
- COVID-19 vaccine/adjuvant testing, benchmarking, and evaluation
Advantages
- Can predict long-term immune response within days of vaccination
- Significantly shortens the time required for vaccine/adjuvant evaluation
Related Links
Patents
- Published Application: 20240369540
Similar Technologies
-
Direct Detection of T cell Mediated Immune Responses Using Peptide MHCs (pMHCs) Displayed on Multimeric Protein Scaffolds S20-371Direct Detection of T cell Mediated Immune Responses Using Peptide MHCs (pMHCs) Displayed on Multimeric Protein Scaffolds
-
MARIA-Neural network for accurate prediction of HLA class II antigen presentation S19-020MARIA-Neural network for accurate prediction of HLA class II antigen presentation
-
TLR7-agonist-nanoparticle vaccine adjuvant S21-063TLR7-agonist-nanoparticle vaccine adjuvant